Literature DB >> 19486597

Pharmacologic management of patients with both heart failure and diabetes.

Michael R MacDonald1, Mark C Petrie, Miles Fisher, John J V McMurray.   

Abstract

Diabetes and heart failure often occur together in patients, with each condition influencing the treatment of the other. Each disease has its own well-documented impact on prognosis, but when they are present in the same patient, the risk of morbidity and mortality increases substantially. Some therapies used in the treatment of diabetes are contraindicated in patients with heart failure, and some therapies for treating heart failure are often mistakenly believed to be contraindicated in patients with diabetes. This article aims to clarify the evidence behind treating these conditions simultaneously and dispel the myths surrounding the pharmacologic management of diabetes in heart failure and vice versa.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19486597     DOI: 10.1007/s11897-009-0019-3

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  48 in total

1.  Standards of medical care in diabetes--2008.

Authors: 
Journal:  Diabetes Care       Date:  2008-01       Impact factor: 19.112

2.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

Authors:  George G Sokos; Lazaros A Nikolaidis; Sunil Mankad; Dariush Elahi; Richard P Shannon
Journal:  J Card Fail       Date:  2006-12       Impact factor: 5.712

3.  Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.

Authors:  Dean T Eurich; Sumit R Majumdar; Finlay A McAlister; Ross T Tsuyuki; Jeffrey A Johnson
Journal:  Diabetes Care       Date:  2005-10       Impact factor: 19.112

4.  Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.

Authors:  Prakash C Deedwania; Thomas D Giles; Michael Klibaner; Jalal K Ghali; Johan Herlitz; Per Hildebrandt; John Kjekshus; Jindrich Spinar; Jiri Vitovec; Hilary Stanbrook; John Wikstrand
Journal:  Am Heart J       Date:  2005-01       Impact factor: 4.749

5.  Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.

Authors:  James B Young; Mark E Dunlap; Marc A Pfeffer; Jeffrey L Probstfield; Alain Cohen-Solal; Rainer Dietz; Christopher B Granger; Jaromir Hradec; Jerzy Kuch; Robert S McKelvie; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Peter Held; Scott D Solomon; Salim Yusuf; Karl Swedberg
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

Review 6.  Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.

Authors:  Dean T Eurich; Finlay A McAlister; David F Blackburn; Sumit R Majumdar; Ross T Tsuyuki; Janice Varney; Jeffrey A Johnson
Journal:  BMJ       Date:  2007-08-30

Review 7.  Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.

Authors:  Steven Joseph Haas; Theo Vos; Richard E Gilbert; Henry Krum
Journal:  Am Heart J       Date:  2003-11       Impact factor: 4.749

Review 8.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Arch Intern Med       Date:  2003-11-24

9.  Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).

Authors:  Michel Komajda; Beatrix Lutiger; Hugo Madeira; Kristian Thygesen; Marco Bobbio; Per Hildebrandt; Wybren Jaarsma; Günter Riegger; Lars Rydén; Armin Scherhag; Jordi Soler-Soler; Willem J Remme
Journal:  Eur J Heart Fail       Date:  2004-06       Impact factor: 15.534

10.  Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.

Authors:  R M Herings; A de Boer; B H Stricker; H G Leufkens; A Porsius
Journal:  Lancet       Date:  1995-05-13       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.